Gut bacteria and diarrhea in breast cancer patients on pyrotinib
Part of Cancer, Skin clinical trials.
This study looks at how gut bacteria relate to diarrhea in breast cancer patients who are taking a drug called pyrotinib. By understanding this link, doctors hope to better manage side effects in the future.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have HER2-positive breast cancer and have been taking pyrotinib for at least 2 weeks.
- You agree to take part in the study and sign a consent form.
- You do not have a serious gut disease (like Crohn's or ulcerative colitis) or have had major gut surgery.
- You have not taken antibiotics, probiotics, or gut-altering herbs in the past month.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a targeted therapy called pyrotinib for people with advanced or metastatic HER2-positive breast cancer. It aims to see how well the drug works in a real-world setting, helping guide treatment for this specific type of cancer.
This trial tests different doses of pyrotinib, a targeted therapy, for women with HER2-positive advanced breast cancer that has not yet been treated for recurrence. It aims to find the best dosing regimen to control the cancer.
This study tests a new way to give pyrotinib, a targeted pill for HER2-positive breast cancer, to people whose cancer has spread or come back and who have not had other treatments for this stage. The goal is to find the best dose to control cancer while managing side effects.
This trial tests whether a special probiotic supplement (good bacteria) can reduce belly discomfort caused by abemaciclib, a hormone therapy drug for early breast cancer. You would take the supplement alongside your cancer treatment to see if it helps with stomach side effects.
This study looks at how the bacteria in your digestive system may affect side effects from abemaciclib, a hormone-based breast cancer drug. By collecting stool samples, researchers hope to understand which patients might experience fewer problems and how to better manage treatment.
This study looks at how gut bacteria affect response to a type of targeted therapy (CDK4/6 inhibitors) combined with hormone therapy in breast cancer that is hormone receptor-positive and HER2-negative. It may help find out why some people respond better to treatment and could lead to better personalized care.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.